CompanyCHRSNasdaqRedwood City, CA

Coherus Oncology, Inc.

Coherus Oncology is a commercial-stage oncology company developing the PD-1 inhibitor toripalimab and a pipeline of antibody immunotherapies targeting liver, head and neck, colorectal, and gastrointestinal cancers.

Stories only

SEC EDGAR ClinicalTrials.gov coherus.com

S-1Aug 28Latest SEC filing

Sep 25Latest story

September 2026

Vanderbilt registers Phase 2 toripalimab trial in esophageal cancer, backed by Coherus

Sep 25Weekly roundup, 2 itemsadalimumab-aqvh adalimumab-atto

August 2026

Coherus Oncology files to sell up to $50 million in stock through Leerink Partners

Aug 28FinancingCoherus Oncology, Inc.

Coherus Oncology refinances debt with new $55 million term loan

Aug 17PartnershipCoherus Oncology, Inc.

Coherus reports Q2 2026 results, flags October data update for tagmokitug

Aug 5Quarterly updateCoherus Oncology, Inc.toripalimab-tpzi